Polina Khrizman
Expertise in
37
conditions

Dr. Polina Khrizman

Oncology | Hematology Oncology
MD Anderson Cancer Center At Cooper
501 Fellowship Road, Suite 102, 
Mount Laurel, NJ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
37
conditions
MD Anderson Cancer Center At Cooper
501 Fellowship Road, Suite 102, 
Mount Laurel, NJ 

Overview

Polina Khrizman is an Oncologist and a Hematologist Oncology provider practicing medicine in Mount Laurel, New Jersey.

Dr. Khrizman is highly rated in 37 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Lung Adenocarcinoma, and Tissue Biopsy.

Dr. Khrizman is board certified in American Board Of Internal Medicine,Medical Oncology , 2012. She is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 6 clinical trials. Dr. Khrizman is currently accepting new patients.

Specialties

Oncology
Hematology Oncology

Licenses

Internal Medicine in IL

Board Certifications

American Board Of Internal Medicine,Medical Oncology , 2012

Fellowships

Northwestern Memorial Hospital,Hematology and Medical Oncology,2011

Hospital Affiliations

Cooper University Hospital
Inspira Medical Center Mullica Hill
Cape Regional Medical Center Inc
Cooper University Hospital

Languages Spoken

English
Russian

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Guardian Life Insurance Company
  • MEDICARE PDP
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

MD Anderson Cancer Center at Cooper
501 Fellowship Road, Suite 102, Mount Laurel, NJ 08054
Other Locations
MD Anderson Cancer Center at Cooper - Camden
2 Cooper Plaza, Camden, NJ 08103

Additional Areas of Focus

Dr. Khrizman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
View 5 Less Clinical Trials

10 Total Publications

Implementation of a next-generation sequencing and PD-L1 immunohistochemistry reflex testing protocol for non-small cell lung cancers improves turnaround time.
Implementation of a next-generation sequencing and PD-L1 immunohistochemistry reflex testing protocol for non-small cell lung cancers improves turnaround time.
Journal: American journal of clinical pathology
Published: June 17, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Margaret T. Kasner
Hematology Oncology | Palliative Medicine | Oncology
Expertise in
18
conditions
Dr. Margaret T. Kasner
Hematology Oncology | Palliative Medicine | Oncology
Referral may be required
Before you request

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
 (10.7 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Margaret Kasner is a Hematologist Oncology specialist and a Palliative Medicine provider practicing medicine in Philadelphia, Pennsylvania. Dr. Kasner is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kasner is board certified in Hematology and Medical Oncology. Dr. Kasner is currently accepting new patients.

Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
Referral may be required
230 W Washington Sq, 2nd Floor, 
Philadelphia, PA 
 (10.4 miles away)
215-829-6088
Languages Spoken:
English
See accepted insurances

Arthur Staddon is a Hematologist Oncology provider practicing medicine in Philadelphia, Pennsylvania. Dr. Staddon is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, and Bone Tumor.

Expertise in
4
conditions
Dr. Rino S. Seedor
Hematology Oncology | Oncology
Expertise in
4
conditions
Dr. Rino S. Seedor
Hematology Oncology | Oncology
Referral may be required
Before you request

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
 (10.7 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rino Seedor is a Hematologist Oncology specialist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Seedor is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Metastatic Uveal Melanoma, Melanoma, Uveal Melanoma, and Melanoma of the Eye. Dr. Seedor is board certified in Medical Oncology. Dr. Seedor is currently accepting new patients.

Frequently Asked Questions about Dr. Polina Khrizman

How do I make an appointment with Dr. Polina Khrizman?

You can book an appointment with Dr. Polina Khrizman by calling their office at 866-632-2667. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Polina Khrizman a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Polina Khrizman is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Polina Khrizman specialize in?

While Dr. Polina Khrizman is a Oncology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Polina Khrizman participate in research or clinical trials?

Yes. Dr. Polina Khrizman has published 10 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Polina Khrizman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Polina Khrizman accept my insurance?

Dr. Polina Khrizman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 866-632-2667 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khrizman's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 22 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile